ERBB2 and colorectal cancer: Some top-ranked candidates were PIM1 in bladder cancer (FDR ≈ 1%), ZFHX4 in colorectal cancer (FDR ≈ 1%), ERBB2 in prostate, stomach, breast luminal subtype, and bladder cancers (FDR ranging from 4% to 14%) and others (Supplementary Fig. S3a).